Researchers at McMaster University have shown that the hormone GDF15 can slow liver inflammation and fibrosis even when weight loss is not a factor, according to a study published Aug. 10, 2026 in Cell Metabolism.
Brain‑to‑organ signaling uncovered
The team used mouse models that mimic human metabolic dysfunction‑associated steatohepatitis (MASH) and applied genetic, pharmacological, genomic and spatial transcriptomics tools. They observed that GDF15 triggers a pathway from the brain to the nervous system, prompting release of glucocorticoids, a class of steroid hormones.
Glucocorticoids then act on the organ to dampen immune activity, shifting immune cells toward a less aggressive state. “Instead of causing damage, GDF15 appears to help calm the organ’s immune system,” said Dongdong Wang, first and corresponding author and assistant professor at McMaster’s Department of Medicine.
In the experiments, mice receiving the hormone showed reduced scar tissue buildup, a hallmark of advanced disease. The findings suggest the pathway works independently of appetite suppression, which was the hormone’s previously known function.
Related: Clinical Trial Joining: The Hurdles You Need to Know
Researchers also examined human data, focusing on individuals carrying a loss‑of‑function variant of the hormone. Those participants displayed higher levels of a biomarker linked to hepatic injury, hinting that deficiency may worsen the condition.
Potential impact on MASH therapy
MASH affects about 7% of the global population and can progress to cirrhosis, cancer or organ failure. It is closely tied to type‑2 diabetes, obesity and other metabolic disorders.
Senior author Gregory Steinberg, professor in the Department of Medicine and co‑director of the Centre for Metabolism, Obesity and Diabetes Research, noted that the discovery “changes how we think about the hormone and suggests it may be part of the body’s own defense system against chronic liver injury.”
Steinberg also co‑founded Espervita Therapeutics, which is testing a compound called EVT0185 that targets metabolic enzymes in the organ and has reduced tumor burden in preclinical models of MASH‑driven hepatocellular carcinoma. He said combining such approaches with anti‑inflammatory strategies could broaden treatment options.
Related: Listen to the Latest KFF Health News Minute
While the mouse work is compelling, the researchers caution that further studies are needed. They plan to test female animals and explore other species to confirm whether the signaling cascade behaves similarly across sexes and models.
It’s a bit odd that the data kinda points that the hormone’s effect might be separate from its appetite‑suppressing role, which could simplify drug development by avoiding weight‑loss side effects.
From a cautious standpoint, if the brain‑organ link holds true in humans, pharmaceutical efforts could aim to amplify the pathway without triggering broader hormonal imbalances. However, translating mouse genetics to patient care often reveals unexpected hurdles, so thorough safety profiling will be essential.
In summary, the study adds a new layer to understanding how the body naturally protects the organ from chronic injury. By mapping a brain‑to‑organ circuit that curtails inflammation, scientists have identified a potential target for future therapies aimed at halting the progression of MASH.
